The Cases and Conversations™: Modifying the Course of Sickle Cell Disease with Modern Interventions

/ Print /
| ShareMore
/ Text Size +
12/10/21 11:00 am EDT
Hyatt Regency Atlanta + Live Streaming

Sickle cell disease is a multisystem disorder caused by a single gene mutation in the beta globin gene. Sickle cell disease has a challenging disease course, with the 2 hallmark symptoms being hemolytic anemia and vaso-occlusion. Pain crisis is the most common reason for seeking treatment, and these pain episodes are associated with significant hospital admissions and negatively impact quality of life. In recent years, several novel therapies have been approved for the management of sickle cell disease, and several additional drugs are currently under development.


Learning Objectives

The learning objectives of this program are:

  • Explain the relationship between the disease course of sickle cell disease and the effect on clinical outcomes
  • Evaluate the role of disease-modifying therapies in the management of patients with sickle cell disease
  • Identify patients with sickle cell disease–related vaso-occlusive pain who are candidates for preventive therapy
  • Select personalized treatment strategies to reduce complications associated with sickle cell disease



Friday, December 10, 2021

Registration and Brunch: 10:15 AM – 11:00 AM EST

Scientific Session: 11:00 AM – 1:30 PM EST



Hyatt Regency Atlanta

In-Person and Live Streaming

Satellite Symposium